Pyocyanin; Pyrocyanine; 5-Methyl-1(5H)-phenazinone; Sanasin; Sanazin
3D model (Jmol)
|Molar mass||210.24 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Pyocyanin (PCN−) is one of the many toxins produced and secreted by the Gram negative bacterium Pseudomonas aeruginosa. Pyocyanin is a blue, secondary metabolite with the ability to oxidise and reduce other molecules and therefore can kill microbes competing against P. aeruginosa as well as mammalian cells of the lungs which P. aeruginosa has infected during cystic fibrosis. Since pyocyanin is a zwitterion at blood pH, it is easily able to cross the cell membrane. There are three different states in which pyocyanin can exist; oxidized, monovalently reduced or divalently reduced. Mitochondria play a huge role in the cycling of pyocyanin between its redox states. Due to its redox-active properties, pyocyanin generates reactive oxygen species.
In order for pyocyanin to be synthesized by P. aeruginosa, two specific genes must be functional. MvfR is a gene which produces a transcription factor which activates phnAB genes. These genes produce the molecule quinolone which then regulates operons 1 and 2 of phzRABCDEFG which are key to the synthesis of phenazine. The synthesis of pyocyanin is primarily controlled by the quorum sensing process. P.aeruginosa strains which are unable to synthesise PCN can still benefit from its effects if the strain has co- infected the lung with wild type strains which can produce pyocyanin. Biosynthesis can be impaired by disrupting the aro pathway which is responsible for the synthesis of chorismic acid from shikimate. Chorismic acid is the precursor of pyocyanin.
- shikimic acid → chorismic acid → phenazine-1-carboxylic acid → 5-methylphenazine-1-carboxylic acid betaine → pyocyanin
The complete virulence of P. aeruginosa can only be experienced when pyocyanin is produced.
Pyocyanin inactivates catalase by reducing its gene’s transcription as well as directly targeting the enzyme itself. Glutathione is an important antioxidant modulated by pyocyanin. In particular the pool of the reduced form is depleted while the oxidised form is promoted by hydrogen peroxide which is not dismutated by catalase. In the cystic fibrosis lung, intracellular pyocyanin converts molecular oxygen to the superoxide free radical by oxidizing NADPH to NADP+. This has a doubly negative effect on the lungs. Firstly, the NADPH used by pyocyanin depletes the available substrate for the reaction catalysed by the NADPH oxidase enzyme. Secondly, the superoxide radical generated can inhibit cytokines such as IL-4, IL-13 and IFN-γ which usually upregulate NADPH oxidase. When the lung is confronted with pyocyanin, an increased concentration of catalase and superoxide dismutase is seen in order to deal with the barrage of radicals being produced.
Pyocyanin is able to target a wide range of cellular components and pathways. Pathways which are affected by pyocyanin include the electron transport chain, vesicular transport, and cell growth. An enhanced susceptibility to pyocyanin is seen in cells which have mutation in certain proteins or complexes. Mutations in genes affecting V-ATPase synthesis and assembly, vesicle transport machinery, protein sorting machinery all confer an increased sensitivity to pyocyanin which further enhances the effects on cystic fibrosis on the patient. Vacuolar- ATPase in yeast cells is a particularly potent target as it is the main non-mitochondrial producer of ATP but also has numerous other functions such as calcium homeostatic control, the facilitation of receptor-mediated endocytosis and the degradation of proteins. Therefore, the inactivation of vacuolar-ATPase by hydrogen peroxide produced by pyocyanin has huge consequences for the lung. Additional to these effects, another target of pyocyanin is caspase 3-like proteases which can then go on to initiate apoptosis and necrosis. Mitochondrial electron carrier’s ubiquinone and nicotinic acid are also susceptible to pyocyanin. The cell cycle can be disturbed by the action of pyocyanin as well as hinder the proliferation of lymphocytes. This is done by the generation of reactive oxygen intermediates such as hydrogen peroxide and superoxide which cause oxidative stress by damaging DNA directly or alternatively targeting other constituents of the cell cycle such as DNA recombination and repair machinery. Pyocyanin contributes to the disproportion of protease and antiprotease activity by disabling α1- protease inhibitor.
Many studies have concluded that pyocyanin has a derogatory effect in cystic fibrosis which enables P. aeruginosa to persist in the cystic fibrosis lung; it is often detected in the sputum from cystic fibrosis patients. Pyocyanin in vitro has the ability to interfere with functions such as ciliary beating and therefore cause epithelial dysfunction as the ciliary are needed to sweep mucus up the throat. Additionally, neutrophil apoptosis, immunoglobulin release from B-lymphocytes and interleukin release e.g. IL-8 and CCL5 are all impaired by pyocyanin causing the immune system of the lung to be weakened. In vivo studies have shown that the growth of fungus is inhibited in the presence of pyocyanin. The fungicidal mechanism is the activation of NAD(P)H to induce a redox active cascade to produce reactive oxygen intermediates. This allows P. aeruginosa to have a competitive advantage as it may dominate over other microorganisms in the cystic fibrosis lung. The intracellular concentration of ATP is also diminished by pyocyanin causing further damage to CFTR which are already impaired in cystic fibrosis. CFTR channels rely on ATP for two main purposes. Firstly, the binding and hydrolysis of ATP has to occur at two nucleotide binding domains for the channel to move between its open and closed conformation. Secondly, phosphorylation of CFTR by Protein kinase A II should occur in order for the channel to be operational. PKA II is activated by cAMP which is produced from ATP. Both these processes are impaired when ATP is depleted by pyocyanin.
Defence against pyocyanin
- Pyocyanin at Sigma-Aldrich
- Hassan H & Fridovich I (1980). "Mechanism of the antibiotic action pyocyanine.". Journal of Bacteriology. 141 (1): 156–163. PMC . PMID 6243619.
- Mavrodi D, Bonsall, R, Delaney, S, Soule, M, Phillips G & Thomashow, L. S. (2001). "Function analysis of genes for biosynthesis of pyocyanin and phenazine -1-carboxamide from Pseudomonas aeruginosa PAO1". Journal of Bacteriology. 183 (21): 6454–6465. doi:10.1128/JB.183.21.6454-6465.2001. PMC . PMID 11591691.
- Lau E, Ran H, Kong F, Hassett D, Mavrodi D (2004). "Pseudomonas aeruginosa Pyocyanin Is Critical for Lung Infection in Mice". Infection and Immunity. 72 (7): 4275–4278. doi:10.1128/IAI.72.7.4275-4278.2004.
- Denning G, Iyer S, Reszka K, O'Malley Y, Rasmussen G, Britigan B (2003). "Phenazine-1-carboxylic acid, a secondary metabolite of Pseudomonas aeruginosa, alters expression of immunomodulatory proteins by human airway epithelial cells". American Journal of Physiology. 285: 584–L592. doi:10.1152/ajplung.00086.2003.
- Lau G, Hassett D, Ran H, Kong F (2004). "The role of pyocyanin in Pseudomonas aeruginosa infection". Trends in Molecular Medicine. 10 (12): 1–666. doi:10.1016/j.molmed.2004.10.002. PMID 15567330.
- Britigin B, Railsback A, Cox D (1999). "The Pseudomonas aeruginosa secretory product pyocyanin inactivates α1 protease inhibitor: implications for the pathogenesis of cystic fibrosis lung disease". Infection and Immunity. 67: 1207–1212.
- Muller M (2002). "Pyocyanin inducesoxidative stress in human endothelialcells and modulates the glutathione redox cycle". Free Radical Biology and Medicine. 33 (11): 1527–1533. doi:10.1016/S0891-5849(02)01087-0.
- Huimin R, Hassett D & Lau G (2003). "Human targets of Pseudomonas aeruginosa pyocyanin". PNAS. 100 (24): 14315–14320. doi:10.1073/pnas.2332354100. PMC . PMID 14605211.
- Ho M, Hirata R, Umemota N, Ohya Y, Takatsuki A, Stevens T, Anraku Y (1993). "VMA13 encodes a 54-kDa vacuolar H(+)ATPase subunit required for activity but not assembly of the enzyme complex in Saccharomyces cerevisiae". The Journal of Biological Chemistry. 268 (24): 18286–18292. PMID 8349704.
- Hassett D, Woodruff W, Wozniak D, Vasil M, Cohen S, Ohman D (1993). "Cloning and characterization of the Pseudomonas aeruginosa soda and sodB genes encoding manganese- and iron cofactored SOD: demonstration of increased Mn SOD dismutase activity in alginate-producing bacteria". Journal of Bacteriology. 175 (23): 7658–65. doi:10.1128/jb.175.23.7658-7665.1993. PMC . PMID 8244935.
- Sorensen R, Klinger J (1987). "Biological effects of Pseudomonas aeruginosa phenazine pigments". Journal of antibiotic Chemotherapy. 39: 113–124. PMID 3118778.
- Kanthakumar K, Taylor G, Tsang K, Cundell D, Rutman A, Smith S, Jeffery P, Cole P, Wilson R (1993). "Mechanism of action of Pseudomona aeruginosa pyocyanin on human ciliary beat in vitro". Infection and Immunity. 61: 2848–2853.
- Usher L, Lawson R, Gaery I, Taylor C, Bingle C, Taylor G, Whyte M (2002). "Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection". The Journal of Immunology. 4: 1861–1868.
- Denning G, Wollenweber L, Railsback M, Cox C, Stoll L, Britigan B (1998). "Pseudomonas pyocyanin increases interleukin-8 expression by human airway epithelial cells". Infection and Immunity. 66 (12): 5777–5784. PMC . PMID 9826354.
- Kerr J, Taylor G, Rutman A, Hoiby N, Cole P, Wilson R (1998). "Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhbit fungal growth". Journal of Clinical Pathology. 52 (5): 385–387. doi:10.1136/jcp.52.5.385.
- Ostedgaard S, Baldursson O, Vermeer D, Welsh M, Robertson A (2001). "Regulation of the cystic fibrosis transmembrane conductance regulator ClK channel by its R domain". Journal of Biological Chemistry. 276 (11): 7689–7692. doi:10.1074/jbc.R100001200.
- Mahajan-Miklos S, Tan M, Rahme L, Ausubel F (1999). "Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model". Cell. 96 (1): 47–56. doi:10.1016/S0092-8674(00)80958-7. PMID 9989496.